Santen Pharmaceutical Co., Ltd. (hereinafter “Santen”) and Eyevance Holdings LLC announced that Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, and Eyevance Holdings LLC entered into a share purchase agreement where Santen Holdings U.S. Inc. acquires all of outstanding shares of Eyevance Pharmaceuticals Holdings Inc. (hereinafter “Eyevance”). Since inception in 2017, Eyevance develops and commercializes topical ophthalmic products targeting the ocular surface and anterior segment. Within this area of focus, Eyevance currently offers anti-inflammatory, anti-allergic, anti-fungal, anti-infective/anti-inflammatory fixed combination, and tear lubricant products.
Read the full article: Santen and U.S. Ophthalmic Company Eyevance Enter into Share Purchase Agreement //
Source: https://www.prnewswire.com/news-releases/santen-and-us-ophthalmic-company-eyevance-enter-into-share-purchase-agreement-301132757.html